A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study

Considering the recent interest in free (unconjugated) curcuminoids delivery, the present study investigated the efficacy of a novel food-grade free-curcuminoids delivery system (curcumin-galactomannoside complex; CGM) in improving the hepatic function markers (inflammation and oxidative stress) in...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2018-01, Vol.2018 (2018), p.1-10
Main Authors: Maliakel, Balu P., Mulakal, Johannah N., Nair, Saritha S., Thomas, Justin V., Krishnareddy, Naveen T., Krishnakumar, I. M.
Format: Article
Language:English
Subjects:
Adult
Alcoholics
Alcoholism
Alcoholism - blood
Alcoholism - drug therapy
Alcoholism - pathology
Alcohols
Antioxidants
Bioavailability
Biomarkers - blood
Cardiovascular disease
Chromatography
Chronic Disease
Clinical Study
Clinical trials
Curcumin
Curcumin - administration & dosage
Double-Blind Method
Drug approval
Drug Delivery Systems - methods
Food
Functional foods & nutraceuticals
gamma-Glutamyltransferase - blood
Good Manufacturing Practice
Herbal medicine
Humans
Inflammation
Interleukin 6
Liver
Liver - metabolism
Liver - pathology
Liver diseases
Male
Markers
Medical research
Metabolism
Metabolites
Middle Aged
Mortality
Novel foods
Oxidative stress
Pathogenesis
Permeability
Randomization
Transaminases
Transaminases - blood
γ-Glutamyltransferase
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Considering the recent interest in free (unconjugated) curcuminoids delivery, the present study investigated the efficacy of a novel food-grade free-curcuminoids delivery system (curcumin-galactomannoside complex; CGM) in improving the hepatic function markers (inflammation and oxidative stress) in chronic alcoholics. The double-blinded, placebo-controlled study randomized 48 subjects with elevated serum transaminases and gamma-glutamyl transferase (GGT) levels, who were allocated to two groups (n=24) and to receive either placebo or CGM at (250 mg × 2)/day for 8 weeks. While liver function markers (transaminases and GGT) in the placebo group showed an increase (~ 9.5%), CGM group indicated a significant decrease in transaminases (31%) and GGT (29%) from the baseline levels. The beneficial effect of CGM was also clear from the significant increase (p
ISSN:2314-6133
2314-6141
DOI:10.1155/2018/9159281